Pfizer
↗New York, United States
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. Founded in 1849 as 'Charles Pfizer & Company' by Charles Pfizer and Charles F. Erhart, Pfizer has grown into one of the world's largest pharmaceutical firms. The company develops and produces medications and vaccines across multiple therapeutic areas including immunology, oncology, cardiology, endocrinology, and neurology. With trailing 12-month revenues of $62.8B as of September 30, 2025, Pfizer operates a global network of manufacturing and research facilities and maintains a strong presence in all major pharmaceutical markets.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Integrated Pharmaceutical Company
SIZE & FINANCIALS
Employees:10000+
Revenue:$61B-$64B
Founded:1849
Ownership:public
Status:operating
FUNDING
Stage:N/A
Total Raised:N/A
STOCK
Exchange:NYSE
Ticker:PFE
Market Cap:$141.57B
PIPELINE
Stage:Phase 1-3 and pending approval
Lead Drug Stage:Phase 3
Modalities:Small molecule, mAb, ADC, Vaccines, RNA-based, Bispecific antibodies, PROTAC
Trial Phases:Phase 1: 47 | Phase 2: 28 | Phase 3: 30
FDA Approvals:50
CORPORATE STRUCTURE
Subsidiaries:Seagen (acquired 2023), Metsera (acquired 2025), Pfizer CentreOne, Pfizer Consumer Healthcare
Key Partnerships:BioNTech: mRNA vaccine development and manufacturing; COVID-19 vaccines (COMIRNATY), RSV vaccine, HPV vaccine, Arvinas: PROTAC ER degrader development; vepdegestrant for ER+ breast cancer, Astellas Pharma: EV-303 trial for muscle-invasive bladder cancer, 3SBio: Exclusive global ex-China licensing agreement for SSGJ-707 (PD-1/VEGF bispecific), Tempus: Expanded alliance for AI-driven precision medicine, Ginkgo Bioworks: RNA-based drug candidate discovery collaboration, Flagship Pioneering: $100M joint initiative to incubate and develop up to 10 novel therapeutic programs
COMPETITION
Position:Leader
Competitors:Merck & Co. ($64.17B FY2024 revenue; Keytruda dominance), Johnson & Johnson ($57.07B pharma revenue), AbbVie ($56.33B), AstraZeneca ($54.07B), Bristol Myers Squibb, Roche, Novartis, Novo Nordisk (obesity market competition) +1 more
LEADERSHIP
Key Executives:
Albert Bourla - Chairman and Chief Executive Officer
Dave M. Denton - Chief Financial Officer and Executive Vice President
Alexandre de Germay - Chief International Commercial Officer and Executive Vice President
Sally Susman - Executive Vice President and Chief Corporate Affairs Officer
Mike McDermott - Chief Global Supply Officer and Executive Vice President
Aamir Malik - Executive Vice President and Chief Business Innovation Officer
Lindsay Havern - Senior Vice President of Executive Operations and Chief of Staff and Counsel to the CEO
Scientific Founders:Charles Pfizer (co-founder, 1849), Charles F. Erhart (co-founder, 1849)
Board Members:Albert Bourla (Chairman and CEO), Mortimer J. Buckley (Director, Audit and Governance/Sustainability Committees; former Chairman and CEO of Vanguard), Cyrus Taraporevala (Director; also serves on Shell plc and Bridgepoint Group plc boards)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Pfizer. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.